• Thurs news: Novartis not joining weight loss race. Pharma marketing and climate change. Roche flu treatment trial. Cercle’s fund raise for women’s health. ICER looks at GSK COPD drugs. See more on our front page

Biogen deflects claims it misled shareholders about Aduhelm's success

Quote
cafead

cafead

Administrator
Staff member
  • cafead   Aug 01, 2022 at 10:32: AM
via As Biogen attempts to shake off its ill-fated Aduhelm launch, the Big Biotech is turning its attention to disgruntled shareholders.

Biogen is angling to parry claims it misled investors on the assumed success of its Alzheimer’s disease med, Aduhelm.

article source
 

<



Similar threads

cafead
Biogen to seek approval for high-dose version of SMA stalwart Spinraza after trial win
Replies
0
Views
13
Pharma/Biotech Companies - In the News
cafead
cafead
cafead
Eisai, Biogen&#039;s Leqembi nabs UK nod, but reimbursement remains elusive
Replies
0
Views
32
Pharma/Biotech Companies - In the News
cafead
cafead
cafead
Biogen sued for alleged PBM kickbacks scheme to boost Tecfidera in wake of generics
Replies
0
Views
73
Pharma/Biotech Companies - In the News
cafead
cafead
cafead
Driven by Leqembi, Biogen beats Q2 expectations, raises full-year outlook
Replies
0
Views
36
Pharma/Biotech Companies - In the News
cafead
cafead
cafead
After EU setback, Eisai/Biogen build case for Leqembi
Replies
0
Views
9
Pharma/Biotech Companies - In the News
cafead
cafead
Top Bottom
Back
Quote